<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25122660</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>Synergic prodegradative activity of Bicalutamide and trehalose on the mutant androgen receptor responsible for spinal and bulbar muscular atrophy.</ArticleTitle><Pagination><StartPage>64</StartPage><EndPage>75</EndPage><MedlinePgn>64-75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddu419</ELocationID><Abstract><AbstractText>Spinal and bulbar muscular atrophy (SBMA) is an X-linked motoneuron disease due to a CAG triplet-repeat expansion in the androgen receptor (AR) gene, which is translated into an elongated polyglutamine (polyQ) tract in AR protein (ARpolyQ). ARpolyQ toxicity is activated by the AR ligand testosterone (or dihydrotestosterone), and the polyQ triggers ARpolyQ misfolding and aggregation in spinal cord motoneurons and muscle cells. In motoneurons, testosterone triggers nuclear toxicity by inducing AR nuclear translocation. Thus, (i) prevention of ARpolyQ nuclear localization, combined with (ii) an increased ARpolyQ cytoplasmic clearance, should reduce its detrimental activity. Using the antiandrogen Bicalutamide (Casodex(&#xae;)), which slows down AR activation and nuclear translocation, and the disaccharide trehalose, an autophagy activator, we found that, in motoneurons, the two compounds together reduced ARpolyQ insoluble forms with higher efficiency than that obtained with single treatments. The ARpolyQ clearance was mediated by trehalose-induced autophagy combined with the longer cytoplasmic retention of ARpolyQ bound to Bicalutamide. This allows an increased recognition of misfolded species by the autophagic system prior to their migration into the nucleus. Interestingly, the combinatory use of trehalose and Bicalutamide was also efficient in the removal of insoluble species of AR with a very long polyQ (Q112) tract, which typically aggregates into the cell nuclei. Collectively, these data suggest that the combinatory use of Bicalutamide and trehalose is a novel approach to facilitate ARpolyQ clearance that has to be tested in other cell types target of SBMA (i.e. muscle cells) and in vivo in animal models of SBMA.</AbstractText><CopyrightInformation>&#xa9; The Author 2014. Published by Oxford University Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giorgetti</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, Milano 20133, Italy Centro InterUniversitario sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Firenze, Genova e Roma Tor Vergata, Milano 20133, Italy Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusmini</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, Milano 20133, Italy Centro InterUniversitario sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Firenze, Genova e Roma Tor Vergata, Milano 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crippa</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, Milano 20133, Italy Centro InterUniversitario sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Firenze, Genova e Roma Tor Vergata, Milano 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cristofani</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, Milano 20133, Italy Centro InterUniversitario sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Firenze, Genova e Roma Tor Vergata, Milano 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boncoraglio</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, Milano 20133, Italy Centro InterUniversitario sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Firenze, Genova e Roma Tor Vergata, Milano 20133, Italy Department of Cell Biology, University Medical Center of Groningen, RB 9700 Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicardi</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, Milano 20133, Italy Centro InterUniversitario sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Firenze, Genova e Roma Tor Vergata, Milano 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galbiati</LastName><ForeName>Mariarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, Milano 20133, Italy Centro InterUniversitario sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Firenze, Genova e Roma Tor Vergata, Milano 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poletti</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, Milano 20133, Italy Centro InterUniversitario sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Firenze, Genova e Roma Tor Vergata, Milano 20133, Italy angelo.poletti@unimi.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GGP14039</GrantID><Acronym>TI_</Acronym><Agency>Telethon</Agency><Country>Italy</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C410798">AR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000726">Androgen Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000813">Anilides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014105">Tosyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>A0Z3NAU9DP</RegistryNumber><NameOfSubstance UI="C053541">bicalutamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>B8WCK70T7I</RegistryNumber><NameOfSubstance UI="D014199">Trehalose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000726" MajorTopicYN="N">Androgen Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000813" MajorTopicYN="N">Anilides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014105" MajorTopicYN="N">Tosyl Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014199" MajorTopicYN="N">Trehalose</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25122660</ArticleId><ArticleId IdType="pmc">PMC4262493</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddu419</ArticleId><ArticleId IdType="pii">ddu419</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kennedy W.R., Alter M., Sung J.H. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology. 1968;18:671&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobue G., Hashizume Y., Mukai E., Hirayama M., Mitsuma T., Takahashi A. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain. 1989;112:209&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">2917278</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M., Tanaka F., Adachi H., Banno H., Suzuki K., Watanabe H., Sobue G. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA) Prog. Neurobiol. 2012;99:246&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">22609045</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352:77&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischbeck K.H. Developing treatment for spinal and bulbar muscular atrophy. Prog. Neurobiol. 2012;99:257&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3460036</ArticleId><ArticleId IdType="pubmed">22668795</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua J.P., Lieberman A.P. Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy. CNS Neurol. Disord. Drug Targets. 2013;12:1146&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003563</ArticleId><ArticleId IdType="pubmed">24040817</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua J.P., Reddy S.L., Merry D.E., Adachi H., Katsuno M., Sobue G., Robins D.M., Lieberman A.P. Transcriptional activation of TFEB/ZKSCAN3 target genes underlies enhanced autophagy in spinobulbar muscular atrophy. Hum. Mol. Genet. 2014;23:1376&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3919011</ArticleId><ArticleId IdType="pubmed">24150846</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z., Wang A.M., Adachi H., Katsuno M., Sobue G., Yue Z., Robins D.M., Lieberman A.P. Macroautophagy is regulated by the UPR-mediator CHOP and accentuates the phenotype of SBMA mice. PLoS Genet. 2011;7:e1002321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192827</ArticleId><ArticleId IdType="pubmed">22022281</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan C.L., Lieberman A.P. Spinal and bulbar muscular atrophy: a motoneuron or muscle disease. Curr. Opin. Pharmacol. 2008;8:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2603477</ArticleId><ArticleId IdType="pubmed">18775514</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes C.J., Ling S.C., Guo L.T., Hung G., Tsunemi T., Ly L., Tokunaga S., Lopez E., Sopher B.L., Bennett C.F., et al. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron. 2014;82:295&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4096235</ArticleId><ArticleId IdType="pubmed">24742458</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman A.P., Yu Z., Murray S., Peralta R., Low A., Guo S., Yu X.X., Cortes C.J., Bennett C.F., Monia B.P., et al. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep. 2014;7:774&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356525</ArticleId><ArticleId IdType="pubmed">24746732</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K., Katsuno M., Banno H., Takeuchi Y., Atsuta N., Ito M., Watanabe H., Yamashita F., Hori N., Nakamura T., et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain. 2008;131:229&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056738</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi H., Katsuno M., Minamiyama M., Waza M., Sang C., Nakagomi Y., Kobayashi Y., Tanaka F., Doyu M., Inukai A., et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain. 2005;128:659&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659427</ArticleId></ArticleIdList></Reference><Reference><Citation>Walcott J.L., Merry D.E. Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy. J. Biol. Chem. 2002;277:50855&#x2013;50859.</Citation><ArticleIdList><ArticleId IdType="pubmed">12388541</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier-Larsen E.S., O'Brien C.J., Wang H., Jenkins S.C., Holder L., Lieberman A.P., Merry D.E. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J. Neurosci. 2004;24:4778&#x2013;4786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729468</ArticleId><ArticleId IdType="pubmed">15152038</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier-Larsen E.S., Merry D.E. Testosterone treatment fails to accelerate disease in a transgenic mouse model of spinal and bulbar muscular atrophy. Dis. Mod. Mech. 2012;5:141&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3255552</ArticleId><ArticleId IdType="pubmed">21954065</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti A. The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons. Front. Neuroendocrinol. 2004;25:1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">15183036</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M., Adachi H., Kume A., Li M., Nakagomi Y., Niwa H., Sang C., Kobayashi Y., Doyu M., Sobue G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35:843&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt B.J., Greenberg C.R., Allingham&#x2013;Hawkins D.J., Spriggs E.L. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology. 2002;59:770&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">12221177</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M., Adachi H., Inukai A., Sobue G. Transgenic mouse models of spinal and bulbar muscular atrophy (SBMA) Cytogenet. Genome Res. 2003;100:243&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">14526186</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z., Dadgar N., Albertelli M., Scheller A., Albin R.L., Robins D.M., Lieberman A.P. Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein. Am. J. Pathol. 2006;168:195&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592669</ArticleId><ArticleId IdType="pubmed">16400023</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M., Banno H., Suzuki K., Takeuchi Y., Kawashima M., Yabe I., Sasaki H., Aoki M., Morita M., Nakano I., et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:875&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi H., Waza M., Katsuno M., Tanaka F., Doyu M., Sobue G. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy. Neuropathol. Appl. Neurobiol. 2007;33:135&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">17359355</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi P., Bendotti C., Simeoni S., Piccioni F., Guerini V., Marron T.U., Martini L., Poletti A. Androgen 5-alpha-reductase type 2 is highly expressed and active in rat spinal cord motor neurones. J. Neuroendocrinol. 2003;15:882&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">12899683</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Rhodes L.E., Kokkinis A.D., White M.J., Watts C.A., Auh S., Jeffries N.O., Shrader J.A., Lehky T.J., Li L., Ryder J.E., et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011;10:140&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056353</ArticleId><ArticleId IdType="pubmed">21216197</ArticleId></ArticleIdList></Reference><Reference><Citation>Renier K.J., Troxell-Smith S.M., Johansen J.A., Katsuno M., Adachi H., Sobue G., Chua J.P., Sun Kim H., Lieberman A.P., Breedlove S.M., et al. Anti-androgen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy. Endocrinology. 2014;155:2624&#x2013;2634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060177</ArticleId><ArticleId IdType="pubmed">24742193</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr C.R., Montie H.L., Liu Y., Bolzoni E., Jenkins S.C., Wilson E.M., Joseph J.D., McDonnell D.P., Merry D.E. An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J. Biol. Chem. 2010;285:35567&#x2013;35577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975181</ArticleId><ArticleId IdType="pubmed">20826791</ArticleId></ArticleIdList></Reference><Reference><Citation>Montie H.L., Cho M.S., Holder L., Liu Y., Tsvetkov A.S., Finkbeiner S., Merry D.E. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2009;18:1937&#x2013;1950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678926</ArticleId><ArticleId IdType="pubmed">19279159</ArticleId></ArticleIdList></Reference><Reference><Citation>Montie H.L., Pestell R.G., Merry D.E. SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA. J. Neurosci. 2011;31:17425&#x2013;17436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6088793</ArticleId><ArticleId IdType="pubmed">22131404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman A.P., Harmison G., Strand A.D., Olson J.M., Fischbeck K.H. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum. Mol. Genet. 2002;11:1967&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman A.P., Robitaille Y., Trojanowski J.Q., Dickson D.W., Fischbeck K.H. Polyglutamine-containing aggregates in neuronal intranuclear inclusion disease. Lancet. 1998;351:884.</Citation><ArticleIdList><ArticleId IdType="pubmed">9525376</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas M., Harrell J.M., Morishima Y., Peng H.M., Pratt W.B., Lieberman A.P. Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction. Hum. Mol. Genet. 2006;15:1876&#x2013;1883.</Citation><ArticleIdList><ArticleId IdType="pubmed">16644868</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas M., Yu Z., Dadgar N., Varambally S., Yu J., Chinnaiyan A.M., Lieberman A.P. The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor. J. Biol. Chem. 2005;280:21264&#x2013;21271.</Citation><ArticleIdList><ArticleId IdType="pubmed">15799970</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas M., Dadgar N., Aphale A., Harrell J.M., Kunkel R., Pratt W.B., Lieberman A.P. Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. J. Biol. Chem. 2004;279:8389&#x2013;8395.</Citation><ArticleIdList><ArticleId IdType="pubmed">14670946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A.M., Miyata Y., Klinedinst S., Peng H.M., Chua J.P., Komiyama T., Li X., Morishima Y., Merry D.E., Pratt W.B., et al. Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat. Chem. Biol. 2013;9:112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552084</ArticleId><ArticleId IdType="pubmed">23222885</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima Y., Wang A.M., Yu Z., Pratt W.B., Osawa Y., Lieberman A.P. CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins. Hum. Mol. Genet. 2008;17:3942&#x2013;3952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605787</ArticleId><ArticleId IdType="pubmed">18784277</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P., Crippa V., Giorgetti E., Boncoraglio A., Cristofani R., Carra S., Poletti A. Clearance of the mutant androgen receptor in motoneuronal models of spinal and bulbar muscular atrophy. Neurobiol. Aging. 2013;34:2585&#x2013;2603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748343</ArticleId><ArticleId IdType="pubmed">23810450</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P., Sau D., Crippa V., Palazzolo I., Simonini F., Onesto E., Martini L., Poletti A. Aggregation and proteasome: the case of elongated polyglutamine aggregation in spinal and bulbar muscular atrophy. Neurobiol. Aging. 2007;28:1099&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pubmed">16781019</ArticleId></ArticleIdList></Reference><Reference><Citation>Simeoni S., Mancini M.A., Stenoien D.L., Marcelli M., Weigel N.L., Zanisi M., Martini L., Poletti A. Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract. Hum. Mol. Genet. 2000;9:133&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">10587588</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccioni F., Pinton P., Simeoni S., Pozzi P., Fascio U., Vismara G., Martini L., Rizzuto R., Poletti A. Androgen receptor with elongated polyglutamine tract forms aggregates that alter axonal trafficking and mitochondrial distribution in motor neuronal processes. FASEB J. 2002;16:1418&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pubmed">12205033</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P., Bolzoni E., Crippa V., Onesto E., Sau D., Galbiati M., Piccolella M., Poletti A. Proteasomal and autophagic degradative activities in spinal and bulbar muscular atrophy. Neurobiol. Dis. 2010;40:361&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">20621188</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo K., Nassif M., Valenzuela V., Rojas F., Matus S., Mercado G., Court F.A., van Zundert B., Hetz C. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy. 2013;9:1308&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">23851366</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M., Machida Y., Niu S., Ikeda T., Jana N.R., Doi H., Kurosawa M., Nekooki M., Nukina N. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 2004;10:148&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">14730359</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S., Davies J.E., Huang Z., Tunnacliffe A., Rubinsztein D.C. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 2007;282:5641&#x2013;5652.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182613</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies J.E., Sarkar S., Rubinsztein D.C. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum. Mol. Genet. 2006;15:23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16311254</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguib Y., Heiseke A., Gilch S., Riemer C., Baier M., Schatzl H.M., Ertmer A. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy. 2009;5:361&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">19182537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan D.M., Liu F.T., Zhao J., Chen Y., Wu J.J., Ding Z.T., Yue Z.Y., Ren H.M., Jiang Y.P., Wang J. Effect of trehalose on PC12 cells overexpressing wild-type or A53 T mutant alpha-synuclein. Neurochem. Res. 2012;37:2025&#x2013;2032.</Citation><ArticleIdList><ArticleId IdType="pubmed">22707286</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Chen S., Song L., Tang Y., Shen Y., Jia L., Le W. MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis. Autophagy. 2014;10:588&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4091147</ArticleId><ArticleId IdType="pubmed">24441414</ArticleId></ArticleIdList></Reference><Reference><Citation>Montie H.L., Merry D.E. Autophagy and access: understanding the role of androgen receptor subcellular localization in SBMA. Autophagy. 2009;5:1194&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pubmed">19770590</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z., Wang A.M., Robins D.M., Lieberman A.P. Altered RNA splicing contributes to skeletal muscle pathology in Kennedy disease knock-in mice. Dis. Mod. Mech. 2009;2:500&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737058</ArticleId><ArticleId IdType="pubmed">19692580</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi H., Waza M., Tokui K., Katsuno M., Minamiyama M., Tanaka F., Doyu M., Sobue G. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J. Neurosci. 2007;27:5115&#x2013;5126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672370</ArticleId><ArticleId IdType="pubmed">17494697</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P., Simonini F., Crippa V., Bolzoni E., Onesto E., Cagnin M., Sau D., Ferri N., Poletti A. 17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy. Neurobiol. Dis. 2011;41:83&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">20816782</ArticleId></ArticleIdList></Reference><Reference><Citation>Carra S., Rusmini P., Crippa V., Giorgetti E., Boncoraglio A., Cristofani R., Naujock M., Meister M., Minoia M., Kampinga H.H., et al. Different anti-aggregation and pro-degradative functions of the members of the mammalian sHSP family in neurological disorders. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2013;368:20110409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3638395</ArticleId><ArticleId IdType="pubmed">23530259</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa V., Sau D., Rusmini P., Boncoraglio A., Onesto E., Bolzoni E., Galbiati M., Fontana E., Marino M., Carra S., et al. The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS) Hum. Mol. Genet. 2010;19:3440&#x2013;3456.</Citation><ArticleIdList><ArticleId IdType="pubmed">20570967</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa V., Carra S., Rusmini P., Sau D., Bolzoni E., Bendotti C., De Biasi S., Poletti A. A role of small heat shock protein B8 (HspB8) in the autophagic removal of misfolded proteins responsible for neurodegenerative diseases. Autophagy. 2010;6:958&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">20699640</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R., Barkhordarian H., Emadi S., Park C.B., Sierks M.R. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol. Dis. 2005;20:74&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16137568</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Fan H., Ying Z., Li B., Wang H., Wang G. Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci. Lett. 2010;469:112&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">19944744</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashman N.R., Durham H.D., Blusztajn J.K., Oda K., Tabira T., Shaw I.T., Dahrouge S., Antel J.P. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Devel. Dyn. 1992;194:209&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">1467557</ArticleId></ArticleIdList></Reference><Reference><Citation>Durham H.D., Dahrouge S., Cashman N.R. Evaluation of the spinal cord neuron X neuroblastoma hybrid cell line NSC-34 as a model for neurotoxicity testing. Neurotoxicology. 1992;14:387&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">7909362</ArticleId></ArticleIdList></Reference><Reference><Citation>Marron T.U., Guerini V., Rusmini P., Sau D., Brevini T.A.L., Martini L., Poletti A. Androgen-induced neurite outgrowth is mediated by neuritin in motor neurones. J. Neurochem. 2005;92:10&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15606892</ArticleId></ArticleIdList></Reference><Reference><Citation>Sau D., De Biasi S., Vitellaro-Zuccarello L., Riso P., Guarnieri S., Porrini M., Simeoni S., Crippa V., Onesto E., Palazzolo I., et al. Mutation of SOD1 in ALS: a gain of a loss of function. Hum. Mol. Genet. 2007;16:1604&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17504823</ArticleId></ArticleIdList></Reference><Reference><Citation>Onesto E., Rusmini P., Crippa V., Ferri N., Zito A., Galbiati M., Poletti A. Muscle cells and motoneurons differentially remove mutant SOD1 causing familial amyotrophic lateral sclerosis. J. Neurochem. 2011;118:266&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206220</ArticleId><ArticleId IdType="pubmed">21554318</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti A., Rampoldi A., Piccioni F., Volpi S., Simeoni S., Zanisi M., Martini L. 5Alpha-reductase type 2 and androgen receptor expression in gonadotropin releasing hormone GT1&#x2013;1 cells. J. Neuroendocrinol. 2001;13:353&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">11264723</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>